Jeff Bockman’s Post

In honour of Breast Cancer Awareness Month this October, 𝐑𝐮𝐝𝐢 𝐕𝐚𝐧 𝐃𝐞𝐧 𝐄𝐲𝐧𝐝𝐞, Head of Thematic Global Equity, shares insights into the disease. 🎗️ 👉 https://lnkd.in/eniZsTtc Pharmaceutical innovation continues to thrive, driven by a deeper understanding of breast cancer. 🧬 Discover the most promising scientific work in the field, including personalized medicine and specialized drugs. New alternatives are emerging, such as FDA-approved treatments for 𝐭𝐫𝐢𝐩𝐥𝐞-𝐧𝐞𝐠𝐚𝐭𝐢𝐯𝐞 cancer and improved therapies for advanced or treatment-resistant cancers. Exciting research also focuses on immunotherapy to bolster the body's defense against tumors. Let's raise awareness and support progress in breast cancer research and treatment. 💗 #CandriamAgainstCancer – together we can make a difference. #Investing4Tomorrow #BreastCancerAwareness #CandriamCares

At #AmplityHealth, our contract sales, medical, and communications experts have a front-row seat in advancing #immunotherapy and #precisionmedicine to combat cancer more effectively with our biopharma clients. Here are some key highlights from #ASCO24 Day 1: - Discussion of newly FDA-approved oncology agents - Presentation of 5 years of data from the CROWN study comparing lorlatinib and crizotinib in new patients with advanced ALK-positive non-small cell lung cancer - Analysis of research into whether circulating tumor DNA can help predict the effectiveness of neoadjuvant chemotherapy and evaluate the prognosis for those with early breast cancer View our full Day 1 summary and join our mailing list for updates: https://lnkd.in/gA3s6Gh7

A paradigm shift continues in the world of oncology… At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago in early June, over 100 Adoptive Cell-relevant abstracts were presented – showcasing the latest advances in oncology and cancer care. We’ve summarized the key takeaways for CAR-T cell therapy ⬇️ 📚 The spotlight was firmly on CAR–T, covering 50% of the abstracts 🧫 58% of abstracts were targeted towards solid tumor indications 🧬 Johnson & Johnson and Legend Biotech's first phase 3 results of CARTITUDE-4 showed the potential for cilta-cel to become a key therapy for patients with multiple myeloma after first relapse. We are proud to be part of an industry that continues to innovate in the fight against cancer. The shift towards CAR–T cell therapy as earlier line treatments, and subsequent expansion of patient access, is a testament to the relentless efforts of researchers, clinicians, industry, and patient advocates worldwide. #ASCO #celltherapy #genetherapy #manufacturingbrighterfutures #biotechnology

The closest you can get to learning through osmosis 😂 Make progress on your oncology journey by learning from expert oncology pharmacists - take advantage of their years of experience! 👇

Today the Journal of the National Comprehensive Cancer Network® (NCCN®) published “Life Years Gained from the FDA Accelerated Approval Program in Oncology: A Portfolio Model.” Our analysis is the first to estimate patient life years gained among cancer patients because the #FDA #AcceleratedApproval Program facilitated access to treatment sooner than traditional approval, demonstrating the impact of policies on patients’ lives. Key findings: -         From 2006 to 2022, the analysis estimated that the program added about 263,000 life years across 69 products for which overall survival data was available, for approximately 911,000 cancer patients. If this timeline was extended to 2026, it would increase to 382,000 years. -         In a subgroup analysis, we estimated that those with an orphan designation had a gain of 145,413 life years in 264,061 patients, a 16.5% gain over standard of care. This analysis supports our position at Johnson & Johnson Innovative Medicine that policies -- and any proposed changes -- should be evidence-based and patient-centric. Thank you to co-authors Agnes Benedict, Gabor Szabo, Kinga Marczell, and Bridget Doherty, MPH for a terrific partnership! Please read the analysis here: https://lnkd.in/edUEcS5j

Meet Carevive at #ASCO24 to learn more about our real-world research on the patient experience in cancer. We will be presenting several posters on Monday morning, June 3. Abstract #11107, funded by Takeda Development Center Americas, Inc., discusses the utilization of electronic patient-reported outcome measures (PRO) for lung cancer in routine clinical care. Conclusions speak to the feasibility of integrating a standard set of multi-domain PRO measures, comparable to the ICHOM/H2O COS, into routine cancer care across multiple sites with consistent patient engagement and provider utilization. 📅 Poster Board 302 | Monday | June 3, 2024 | 9:00 AM-12:00 PM CDT Feasibility and utilization of electronic patient-reported outcome measures for lung cancer in routine clinical care. Authors: Ethan Basch, Huamao Lin, Mary Lynn Cala, Melpomeni Styliadou, Aaron Galaznik, Debra Wujcik, Emelly Rusli, Nicholas Coombs, Emily Beamon Organizations: The University of North Carolina at Chapel Hill, Takeda Development Center Americas, Inc., Takeda Pharmaceutical Company Limited, Carevive Systems, Inc., Piedmont Research Strategies Aaron Galaznik, Emelly Rusli, Mordecai Kramer, Keri Collette, Bruno Lempernesse #carevive #digitaloncology #cancer #cancercare   #oncology #patientreportedoutcomes #oncologydata   #clinicalinnovation #drugcommercialization #RWD #RWE #smartdata

In 2023, CareAcross led significant advancements, enhancing cancer patients' quality of life and elevating cancer care: - ASCO: Showcasing the power of patient-reported outcomes (PROs) to gain insights beyond cancer patients' experiences. - ESMO: Analysing the impact of our personalised support service for cancer patients through a randomised clinical trial. - Participation at the European Parliament on Advanced Therapies, representing All.Can International. - Moderating a session at the Economist Impact events World Cancer Series, exploring how personalised digital support enhances the quality of life for cancer patients. - Recognised by EFPIA - European Federation of Pharmaceutical Industries and Associations as an innovator in sustainable cancer care. Explore our world of cancer care innovation: https://lnkd.in/dDg57ZtT

At #AmplityHealth, our contract sales, medical, and communications experts have a front-row seat in advancing #immunotherapy and #precisionmedicine to combat cancer more effectively with our biopharma clients. Here are some key highlights from #ASCO24 Day 1: - Discussion of newly FDA-approved oncology agents - Presentation of 5 years of data from the CROWN study comparing lorlatinib and crizotinib in new patients with advanced ALK-positive non-small cell lung cancer - Analysis of research into whether circulating tumor DNA can help predict the effectiveness of neoadjuvant chemotherapy and evaluate the prognosis for those with early breast cancer View our full Day 1 summary and join our mailing list for updates: https://lnkd.in/euzvmUPG

Precision oncology holds the promise of treating each patient with the exact right medicine. However, there are still many barriers that prevent most cancer patients from reaping its benefits. We are thrilled to introduce our groundbreaking “New Medicines, Novel Insights” report, a beacon of hope for better patient outcomes through precision oncology. Featuring inspiring stories from cancer survivors and expert insights on clinical trial design, regulatory strategies, market access and more, this report doesn't just highlight the challenges faced by drug developers—it offers actionable strategies to expedite the journey of precision cancer medicines to the market. Explore the full report and hear firsthand from our Global Head of Oncology, Gwyn Bebb, as he shares his vision and promise for accelerating the development and approval of groundbreaking precision oncology treatments. Dare to dream with us, and together, let's revolutionize cancer care. https://lnkd.in/eXHVeJNf #PrecisionOncology #NewMedicines #NovelInsights #PatientOutcomes